VWD Connect Foundation
Welcome,         Profile    Billing    Logout  
 12 Trials 
12 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Walsh, Christopher A
NCT01160783: Genetic Contributions to Autism Spectrum Disorders

Active, not recruiting
N/A
240
US
Boston Children's Hospital
Autism Spectrum Disorder, Autism, Asperger's Syndrome, Pervasive Developmental Disorder
12/27
02/28
NCT00910559: Phenotypic and Genetic Factors in Autism Spectrum Disorders

Active, not recruiting
N/A
1500
US
Boston Children's Hospital, National Institute of Mental Health (NIMH)
Autism Spectrum Disorders
01/27
02/27
NCT00041600: Human Epilepsy Genetics--Neuronal Migration Disorders Study

Recruiting
N/A
3500
US
Harvard University Faculty of Medicine, National Institute of Neurological Disorders and Stroke (NINDS), Howard Hughes Medical Institute
Brain Malformation, Neuronal Migration Disorder, Cognition Disorder, Epilepsy
06/30
06/30
NCT05437536: The Severe Von Willebrand Disease (sVWD) Patient Registry

Recruiting
N/A
400
US
VWD Connect Foundation
VWD - Von Willebrand's Disease
01/27
01/27
Gounder, nal
A091105, NCT02066181: Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

Checkmark From A091105 clinical trial for rare sarcomas
Mar 2018 - Mar 2018: From A091105 clinical trial for rare sarcomas
Completed
3
87
Canada, US
Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54-9085, Nexavar, sorafenib
National Cancer Institute (NCI)
Desmoid Fibromatosis
07/19
12/22
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting
2/3
192
Europe, US, RoW
AL102, Placebo
Immunome, Inc.
Desmoid, Desmoid Tumor
10/25
10/26
TNG908-C101, NCT05275478 / 2021-005605-27: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Active, not recruiting
1/2
192
Europe, US
TNG908
Tango Therapeutics, Inc., Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
04/25
09/25
NCT05228015: Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Terminated
1
67
Europe, US, RoW
IK-930, Osimertinib
Ikena Oncology
Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE), NF2 Deficient Mesothelioma, Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes, NF2 Deficiency, YAP1 or TAZ Gene Fusions
08/24
09/24
FHD-609-C-001, NCT04965753 / 2021-001488-25: FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors

Terminated
1
55
Europe, US
FHD-609
Foghorn Therapeutics Inc., Foghorn Therapeutics Inc.
Advanced Synovial Sarcoma
12/23
12/23
NCT05437536: The Severe Von Willebrand Disease (sVWD) Patient Registry

Recruiting
N/A
400
US
VWD Connect Foundation
VWD - Von Willebrand's Disease
01/27
01/27
Morgenthaler, Christina
NCT05437536: The Severe Von Willebrand Disease (sVWD) Patient Registry

Recruiting
N/A
400
US
VWD Connect Foundation
VWD - Von Willebrand's Disease
01/27
01/27
Arapshian, Alice
NCT05437536: The Severe Von Willebrand Disease (sVWD) Patient Registry

Recruiting
N/A
400
US
VWD Connect Foundation
VWD - Von Willebrand's Disease
01/27
01/27

Download Options